Display options
Cite
Elmholdt TR, Jørgensen B, Ramsing M, et al. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus. 2010;3(3):285-287doi: 10.1093/ndtplus/sfq028.
Elmholdt, T. R., Jørgensen, B., Ramsing, M., Pedersen, M., & Olesen, A. B. (2010). Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT plus, 3(3), 285-287. https://doi.org/10.1093/ndtplus/sfq028
Elmholdt, Tina Rask, et al. "Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol." NDT plus vol. 3,3 (2010): 285-287. doi: https://doi.org/10.1093/ndtplus/sfq028
Elmholdt TR, Jørgensen B, Ramsing M, Pedersen M, Olesen AB. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus. 2010 Jun;3(3):285-287. doi: 10.1093/ndtplus/sfq028. Epub 2010 Mar 19. PMID: 28657062; PMCID: PMC5477958.
Copy Download .nbib Format: NLM
Share it on

NDT Plus. 2010 Jun;3(3):285-287. doi: 10.1093/ndtplus/sfq028. Epub 2010 Mar 19.

Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol.

NDT plus

Tina Rask Elmholdt, Bettina Jørgensen, Mette Ramsing, Michael Pedersen, Anne Braae Olesen

Affiliations

  1. MR Research Centre.
  2. Institute of Clinical Medicine.
  3. Department of Dermatology.
  4. Department of Nephrology.
  5. Department of Pathology, Aarhus University Hospital, Aarhus, Denmark.

PMID: 28657062 PMCID: PMC5477958 DOI: 10.1093/ndtplus/sfq028

Abstract

Nephrogenic systemic fibrosis (NSF) is a disease with progressive fibrosis. We describe two cases of NSF after exposure to a macrocyclic gadolinium-based contrast agent (GBCA) gadobutrol, which has been considered as a low-risk agent compared to linear GBCAs. The first case had chronic kidney disease (CKD) Stage 3 and was exposed to 17.5 ml of gadobutrol. The second case has been exposed twice to GBCA: 10 ml of gadodiamide (in 2001) and 15 ml of gadobutrol (in 2008). Before the second exposure, he had CKD Stage 5 and was in haemodialysis. Both patients have been diagnosed with NSF. Our cases suggest that cyclic GBCAs can also cause NSF.

Keywords: chronic kidney disease; contrast-enhanced MRI; gadobutrol; nephrogenic systemic fibrosis

References

  1. Kidney Int. 2008 Jun;73(12):1413-8 - PubMed
  2. J Am Soc Nephrol. 2006 Sep;17(9):2359-62 - PubMed
  3. J Magn Reson Imaging. 2009 Dec;30(6):1249-58 - PubMed
  4. Lancet. 2000 Sep 16;356(9234):1000-1 - PubMed
  5. Semin Dial. 2008 Mar-Apr;21(2):129-34 - PubMed
  6. Nephrol Dial Transplant. 2009 Dec;24(12):3882-4 - PubMed
  7. Arch Dermatol. 2009 Feb;145(2):183-7 - PubMed
  8. Semin Dial. 2008 Mar-Apr;21(2):135-9 - PubMed
  9. Br J Dermatol. 2008 Feb;158(2):273-80 - PubMed
  10. Eur J Radiol. 2008 May;66(2):191-9 - PubMed

Publication Types